美国多种族重度高胆固醇血症患者长期死亡率分析
他汀使用随时间下降。
要点
- LDL-C每升高20 mg/dL,9年全因死亡风险增加8%。
- 他汀使用随时间下降,2019-2020年一级预防仅56%使用。
核心结论
- 在LDL-C≥190 mg/dL的多种族美国队列中,识别出多个与9年全因死亡风险增加相关的患者特征,并观察到降脂治疗与生存获益相关。
主要发现
- 调整后LDL-C每升高20 mg/dL与9年死亡风险增加相关(调整HR 1.08,95%CI 1.05-1.11),甘油三酯每升高20 mg/dL亦相关(调整HR 1.04,95%CI 1.02-1.06)。
- 男性(调整HR 1.31,95%CI 1.08-1.58)、年龄每增5岁(调整HR 1.19,95%CI 1.15-1.23)、高血压(调整HR 2.01,95%CI 1.57-2.57)、慢性肾病(调整HR 1.68,95%CI 1.36-2.09)、糖尿病(调整HR 1.79,95%CI 1.50-2.15)、心衰(调整HR 1.51,95%CI 1.16-1.95)、心肌梗死(调整HR 1.41,95%CI 1.05-1.90)及BMI<20 kg/m2(调整HR 3.36,95%CI 2.29-4.93)与更高死亡风险相关。
- 降脂治疗与生存获益相关(调整HR 0.57,95%CI 0.42-0.77);一级预防组中HDL-C<40 mg/dL与更高死亡风险独立相关(调整HR 1.49,95%CI 1.06-2.09)。
- 他汀使用随时间下降(P<0.001),2019-2020年一级预防组56%、二级预防组85%使用他汀。
临床怎么用
- 对LDL-C≥190 mg/dL患者应早期识别并坚持降脂治疗,尤其关注一级预防中他汀使用不足的问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tools for mortality prediction in patients with the severe hypercholesterolemia phenotype (low-density lipoprotein cholesterol ≥190 mg/dL) are limited and restricted to specific racial and ethnic cohorts. We sought to evaluate the predictors of long-term mortality in a large racially and ethnically diverse US patient cohort with low-density lipoprotein cholesterol ≥190 mg/dL. METHODS: We conducted a retrospective analysis of all patients with a low-density lipoprotein cholesterol ≥190 mg/dL seeking care at Montefiore from 2010 through 2020. Patients <18 years of age or with previous malignancy were excluded. The primary end point was all-cause mortality. Analyses were stratified by age, sex, and race and ethnicity. Patients were stratified by primary and secondary prevention. Cox regression analyses were used to adjust for demographic, clinical, and treatment variables. RESULTS: A total of 18 740 patients were included (37% non-Hispanic Black, 30% Hispanic, 12% non-Hispanic White, and 2% non-Hispanic Asian patients). The mean age was 53.9 years, and median follow-up was 5.2 years. Both high-density lipoprotein cholesterol and body mass index extremes were associated with higher mortality in univariate analyses. In adjusted models, higher low-density lipoprotein cholesterol and triglyceride levels were associated with an increased 9-year mortality risk (adjusted hazard ratio [HR], 1.08 [95% CI, 1.05-1.11] and 1.04 [95% CI, 1.02-1.06] per 20-mg/dL increase, respectively). Clinical factors associated with higher mortality included male sex (adjusted HR, 1.31 [95% CI, 1.08-1.58]), older age (adjusted HR, 1.19 per 5-year increase [95% CI, 1.15-1.23]), hypertension (adjusted HR, 2.01 [95% CI, 1.57-2.57]), chronic kidney disease (adjusted HR, 1.68 [95% CI, 1.36-2.09]), diabetes (adjusted HR, 1.79 [95% CI, 1.50-2.15]), heart failure (adjusted HR, 1.51 [95% CI, 1.16-1.95]), myocardial infarction (adjusted HR, 1.41 [95% CI, 1.05-1.90]), and body mass index <20 kg/m2 (adjusted HR, 3.36 [95% CI, 2.29-4.93]). A significant survival benefit was conferred by lipid-lowering therapy (adjusted HR, 0.57 [95% CI, 0.42-0.77]). In the primary prevention group, high-density lipoprotein cholesterol <40 mg/dL was independently associated with higher mortality (adjusted HR, 1.49 [95% CI, 1.06-2.09]). Temporal trend analyses showed a reduction in statin use over time (P<0.001). In the most recent time period (2019-2020), 56% of patients on primary prevention and 85% of those on secondary prevention were on statin therapy. CONCLUSIONS: In a large, diverse cohort of US patients with the severe hypercholesterolemia phenotype, we identified several patient characteristics associated with increased 9-year all-cause mortality and observed a decrease in statin use over time, in particular for primary prevention. Our results support efforts geared toward early recognition and consistent treatment for patients with severe hypercholesterolemia.
引用
- Miles J, Scotti A, Castagna F, et al. Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort. Circulation. 2023. PMID: 37970713. doi:10.1161/CIRCULATIONAHA.123.064566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。